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PPARg is obligatory for fat mass generation and is thought to determine the amount of TAG stored per fat cell. We investigated whether ligand
availability for PPARg is rate limiting in fat mass generation and substrate metabolism. Twenty healthy men (20–29 years) were randomly
assigned to receive the PPARg ligand rosiglitazone (RSG) (8 mg/d) (n 10) or a placebo (n 10) during a stay of 7 d in a respiration chamber.
Food intake was ad libitum, resulting in positive energy balances of 32·2 MJ (placebo) and 44·7 MJ (RSG). Fat cell size and expression of
PPARg, adipocyte fatty acid-binding protein (aP2), adipsin, adiponectin and fasting-induced adipose factor (FIAF) were determined in subcu-
taneous abdominal fat biopsies. The total amount of fat stored and the amount of TAG per fat cell were not different between groups. For the
entire group, fat cell size was decreased after overeating (P¼0·02). FIAF mRNA levels were decreased after overeating in the RSG group
(P¼0·01), with a trend towards a decrease in the placebo group. Unexpectedly, RSG treatment did not influence the expression levels of
PPARg and of the PPARg responsive genes aP2, adiponectin and adipsin. In addition, RSG resulted in a larger increase in plasma TAG
during overeating than placebo treatment. These results suggest that in healthy, non-obese males the PPARg ligand RSG influences TAG metab-
olism, independent of its PPARg transcriptional activity in the subcutaneous adipose tissue.
Ligand: Fat cell size: Adipose tissue: Gene expression: Man
The increasing prevalence of obesity is a major health pro-
blem as obesity is associated with chronic diseases, which
include type II diabetes and CVD1. An excessive adipose
tissue mass, the main feature of obesity, is the result of an
energy intake that exceeds energy expenditure for longer
periods. Yet the molecular mechanisms contributing to the
development of obesity remain ill-defined. Fat mass gener-
ation depends on an increased volume of adipocytes (hypertro-
phy), the recruitment of new adipocytes (hyperplasia),
decreased apoptosis of adipocytes or a combination of these
processes2. Obesity accompanied by metabolic disturbances
(including insulin resistance, increased production of NEFA,
leptin and TNFa) is typically associated with hypertrophy of
the fat cells3.
PPARg, a member of the nuclear hormone receptor super-
family of transcription factors, is required for adipogenesis,
which involves the differentiation of preadipocytes into
fat-storing mature adipocytes4. PPARg regulates the
expression of numerous genes involved in fat storage, includ-
ing adipocyte fatty acid-binding protein (aP2), lipoprotein
lipase and CD36. In addition, PPARg is involved in the
regulation of insulin sensitivity4,5. The importance of
PPARg activity in the regulation of fat mass is emphasized
by PPARg mutations. Dominant-positive PPARg mutations
are associated with severe obesity6, while dominant-negative
PPARg mutations are associated with partial lipodystrophy7.
Activation of DNA transcription by PPARg requires the bind-
ing of a ligand, as well as the presence of several transcrip-
tional regulators and cofactors8. Natural ligands for PPARg
include PUFA and eicosanoids9; synthetic ligands include
rosiglitazone (RSG), which is widely and effectively used in
the treatment of type II diabetes mellitus for its insulin-sensi-
tizing effects10. Treatment with RSG and other thiazolidine-
diones is accompanied by weight gain in rodents11,12 and
obese, diabetic patients13. In rats, this is due to an increased
food intake and an increased feed efficiency12. However, the
molecular and metabolic basis for the weight gain in obese
diabetic patients is not completely clear. We recently overfed
healthy, non-obese females and our results suggested that the
ability to increase PPARg activity may be involved in the
susceptibility to gain weight14. As PPARg activity depends
on ligand binding, the availability of ligand might be involved.
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RSG appears to have its main effects on the adipose tissue, as
RSG does only improve glucose and insulin levels in lipo-
atrophic, diabetic mice after fat transplantation15. Specifically,
RSG seems to affect the subcutaneous adipose tissue as only
human subcutaneous, but not visceral, preadipocytes could be
differentiated in vitro with RSG16 and RSG increased subcu-
taneous, but not visceral, white adipose tissue in rats17. In vivo,
RSG has been shown to increase the expression of PPARg
response genes in type II diabetic patients18. We hypothesized
that if PPARg ligand levels are rate limiting in fat mass gener-
ation during overeating, RSG supplementation will increase
subcutaneous fat storage. To address this question, healthy,
non-obese males were exposed to an obesity-promoting environ-
ment while receiving either a placebo or RSG and the amount of
TAG stored per fat cell, adipose gene expression, hormones
involved in fat storage (insulin, leptin) and substrate availability
(glucose, TAG) were determined.
Subjects and methods
Subjects
The present study was part of a study investigating the effects
of the PPARg ligand RSG on energy balance regulation,
which is described previously19. Subjects had to be male,
between the age of 18 and 40 years, Caucasian, healthy and
have a BMI between 20 and 32 kg/m2. They had to be unrest-
rained eaters, i.e. no desire to restrain intake, as indicated by
scores #9 on factor 1 of the Three-Factor Eating Question-
naire, which reflects the extent to which individuals try to cog-
nitively control their food intake20. Subjects completed a
medical questionnaire before entering the study; only subjects
in good health were included. Subjects who followed a dietary
regimen with the aim to lose or gain weight within 1 year prior
to the study were excluded. The study design required that the
subjects were not fully informed about the adipogenic effect of
the PPARg agonist RSG as this could influence self-selected
food and energy intake and activity-induced energy expendi-
ture. Therefore, subjects were informed that they would
receive either a substance that influences fat metabolism or
a non-active substance (placebo) in a double-blind manner
(i.e. neither the subject nor the investigator knew what the
subject received during the experiment). The study was
approved by the Ethics Committee of Maastricht University.
All subjects received verbal and written information and
signed a written consent form. Twenty men between the age
of 20 and 29 years participated in the study. Characteristics
of the subjects are shown in Table 1.
Experimental design
Subjects were studied during a stay in the respiration chamber
for 7 consecutive days for energy expenditure measurements
calculated from VO2, CO2 production and urinary N excretion
according to the formula of Brouwer 21. The respiration
chamber measures 14 m3 and is furnished with a bed, chair,
table, TV, radio, telephone, computer, washbowl and toilet
facilities22.
Following a double-blind, placebo-controlled design, sub-
jects were randomly assigned to receive either 8 mg/d RSG
(Avandia; GlaxoSmithKline BV, The Netherlands) or placebo
orally. Drugs were dosed twice daily for the total stay of 7 d in
the respiration chamber. Subjects were asked to eat ad libitum
from an excess of food supplied at each mealtime and as
snacks to induce a positive energy balance. No exercise proto-
col was imposed, but sleeping during daytime and strenuous
physical activity were not allowed. Subjects were woken up
between 08.00–08.30 hours, they were free to choose their
bedtimes in the evening. Body composition was determined
by underwater weighing and deuterium dilution (day 1) or
by deuterium dilution alone (day 8). On the same days,
blood samples and fat biopsies were taken. Fat storage was
calculated as the difference between fat intake and fat
oxidation.
Dietary intake
Meals consisting of typically Dutch food items were provided
three times per d, breakfast between 08.30–09.00 hours, lunch
between 12.30–13.00 hours and dinner between 18.00–18.30
hours. Breakfast and lunch consisted of bread, savoury and
sweet condiments, fruit, yoghurt, milk, fruit juice, instant
coffee (decaffeinated) and tea. For dinner, subjects could
choose between ready prepared potato-, pasta- or rice-based
meals with only vegetables or with vegetables plus meat or
fish. They were allowed two alcoholic consumptions, white
or red wine or beer, per d. A wide variety of snacks was con-
tinuously available in the chamber in packages that were
replaced every morning. Snacks consisted of savoury items
(crisps, nuts), sweet items (chocolate bars, sweets), various
biscuits, fruit (apple, orange, banana), instant soup, fruit
juice, instant coffee (decaffeinated) and tea. Meals and
snacks were supplied in excess to be eaten ad libitum; extra
food items were readily available on request. All foods and
drinks entering and leaving the respiration chamber were
weighed to the nearest gram. Energy content and macronutri-
ent composition of the diets were calculated using the Dutch
food composition table23.
Procedures
Anthropometry and body composition. Measurements were
carried out in the morning after voiding and before breakfast.
Body weight and height were measured to the nearest 0·01 kg
and 0·1 cm respectively. BMI (kg/m2) was calculated as body
weight (kg) divided by height (m) squared. Body density was
determined by underwater weighing with simultaneous
Table 1. Baseline characteristics of the subjects*
(Mean values with their standard errors)
Placebo (n 10) RSG (n 10)
Mean SE Mean SE
Age (years) 22 1 24 1
Height (m) 1·83 0·02 1·84 0·02
Body weight (kg) 80·2 3·5 85·7 3·6
BMI (kg/m2) 24·0 1·3 25·1 0·7
Body fat (%) 19·6 1·9 20·3 2·4
* For details of subjects and procedures, see Subjects and methods.
RSG, rosiglitazone.
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measurement of residual lung volume with the He dilution
technique. Total body water was determined with deuterium
dilution following the Maastricht protocol24. Body compo-
sition was calculated from body density and total body
water using the three-compartment model of Siri25.
Blood parameters. After an overnight fast, blood samples
were obtained and mixed with citrate to prevent clotting.
Plasma was obtained by centrifugation (48C, 3000 rpm,
10 min), frozen in liquid N and stored at 2808C until analysis
of concentrations of glucose (hexokinase method, Glucose HK
125 kit; ABX diagnostics, Montpellier, France), insulin
(ELISA, Mercodia, Uppsala, Sweden), leptin (double-antibody
RIA, human leptin specific RIA kit, Linco Research Inc.,
St Charles, USA), TAG (Triglycerides liquicolor kit; Instru-
chemie, Delfzijl, The Netherlands), NEFA (Wako NEFA
C-kit, Wako Chemicals, Neuss, Germany) and HDL-choles-
terol (HDL cholesterol liquicolor kit; Instruchemie).
Adipose tissue and RNA isolation. Abdominal subcu-
taneous fat biopsies (approximately 500 mg) were obtained
by needle liposuction under local anaesthesia (lidocain 2 %,
AstraZeneca BV, Nederland) after an overnight fast. The
tissue was immediately washed in cold PBS and cut into
pieces with a scalpel. Then, tissue for mRNA analysis was
immediately homogenized in 1 ml Trizol (Invitrogen Life
Technologies, Carlsbad, CA, USA) in a mini-beadbeater
(Biospec Products, Bartlesville, OK, USA), frozen in liquid
N and stored at 2808C until RNA extraction. Adipocytes
were isolated from the remaining fresh tissue as described
before26. Briefly, the pieces of fat tissue were digested in
5 ml Dulbecco’s modified Eagle’s medium (DMEM/F12; Invi-
trogen Life Technologies) containing 4 % bovine serum albu-
min (Sigma-Aldrich Co, St Louis, MO, USA) and 2 mg/ml
collagenase II (Sigma) in an incubator (378C, 5 % CO2) on a
shaking platform (200 rpm) for 120 min. The digest was trans-
ferred to a 5 ml syringe and gently pressed over a 500mm ster-
ile disposable filter (Schleicher & Schuell MicroScience,
Dassel, Germany). The syringe was rinsed with 5 ml
DMEM/F12 containing 4 % bovine serum albumin, which
was added to the digest. After centrifugation (1000 rpm,
1 min), the layer of adipocytes floating on top was removed,
frozen in liquid N and stored at 2808C until analysis of cell
size by means of TAG and DNA content.
Total RNA was isolated using the method of Chomczynski
and Sacchi27 and 10mg glycogen (Roche Diagnostics GmbH,
Mannheim, Germany) was added to each sample. Extracted
RNA was quantified and assessed for purity using the Nano-
Drop (NanoDrop Technologies, Wilmington, DE, USA) and
gel electrophoresis (Agilent Technologies, The Netherlands).
Quantification of mRNA expression by real-time RT-PCR.
cDNA synthesis and PCR reactions were performed
as described previously14. The primer sequences were as fol-
lows: PPARg forward 50-TCCATGCTGTTATGGGTGAA-30,
reverse 50-TCAAAGGAGTGGGAGTGGTC-30; aP2 forward
50-GCATTCCACCACCAGTTTATC-30, reverse 50-CAGGA-
AAGTCAAGAGCACCAT-30; fasting-induced adipose factor
(FIAF) forward 50- CACAGCCTGCAGACACAACTC-30,
reverse 50-GGAGGCCAAACTGGCTTTGC-30; adipsin for-
ward 50- TAGCGCGACTCCATCTCTACAA-30, reverse 50-
GCCTCCTGAGTAGCTGGAACT-30; adiponectin forward
50-TATCCCCAACATGCCCATTCG-30, reverse 50-TGGTA-
GGCAAAGTAGTACAGCC-30; 36B4 forward 50- CGGGAA-
GGCTGTGGTGCTG-30, reverse 50-GTGAACACAAAGCC-
CACATTCC-30; b-actin forward 50-AGAAAATCT-GGCAC-
CACACC-30, reverse 50-AGAGGCGTACAGGGATAGCA-
30. For target and housekeeping genes, standard curves were
created from a specific PCR product14. To account for differ-
ences in RNA loading, target mRNA was expressed relative to
b-actin and relative to 36B4 mRNA. As both housekeeping
genes gave the same normalized quantities, target mRNA
levels are presented after normalization to b-actin.
For determination of TAG and DNA in adipocytes, about
40 mg adipocytes was incubated in a volume of 160ml con-
taining 0·1 M-NaCl, 0·02 M-Tris pH 7·4, 0·01 M-EDTA pH
7·5, 100mg/ml proteinase K and 0·05 % Triton X-100 for
60 min at 658C, followed by 10 min at 958C. Of this solution,
10ml was 100 £ diluted before determination of TAG (GPO-
trinder 337; Sigma). For DNA determination, the remaining
solution was mixed with SDS, RNase A and proteinase K to
make final concentrations of 0·5 %, 20mg/ml and 100mg/ml
respectively. After an overnight incubation at 378C, DNA
was precipitated using ethanol precipitation and a high-salt
solution (Kac), rinsed with 70 % ethanol and resuspended in
20ml H2O. DNA was quantified and assessed for purity
using the NanoDrop (NanoDrop Technologies). The mean adi-
pocyte cell size was calculated as mg TAG/cell (mean DNA
content per cell is 6 pg).
Statistical analysis
Results are presented as means with their standard errors or as
median (inter-quartile range). Measurements on the morning
of day 1 before entering the respiration chamber are referred
to as baseline; measurements on the morning of day 8 after
the 7-d respiration chamber stay are referred to as overeating.
Effects of overeating within groups were analysed with Stu-
dent’s paired t test (two-sided) or Wilcoxon’s paired signed
rank test (two-sided) where appropriate. Effects of RSG treat-
ment (between-group effects) were analysed with the Mann–
Whitney U -test (two-sided). Significance of correlations was
tested with the Spearman rank correlation (rS). P,0·05 was
considered statistically significant. SPSS 11 for Macintosh
(SPSS Inc., Chicago, IL, USA) was used for the analysis.
Results
Obesity-promoting environment
For both groups, energy intake (placebo 15·9 (SE 0·9) MJ/d v.
RSG 18·9 (SE 1·2) MJ/d, P¼0·06) was higher than energy
expenditure (placebo 11·3 (SE 0·3) MJ/d v. RSG 12·5 (SE 0·5)
MJ/d, P¼0·09). By the end of day 7, the cumulative energy
balances were 32·2 (SE 5·1) MJ and 44·7 (SE 6·9) MJ for the
placebo and the RSG groups respectively, which was not stat-
istically significant different due to the high inter-individual
variation in both groups (P¼0·16). Body weight increased
by 1·39 (SE 0·37) kg (P,0·01) in the placebo group and by
2·54 (SE 0·53) kg (P¼0·001) in the RSG group. Changes in
body weight did not differ significantly between treatments
(P¼0·09). However, body weight change on RSG was
accompanied with an increase in total body water of 1·6
(SE 0·6) litres (P,0·05), whereas total body water did not
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significantly change in the placebo group (–0·2 (SE 0·7) litres,
P¼0·79).
Rosiglitazone causes elevated TAG levels
In the placebo group, plasma glucose and NEFA were decreased
and TAG was increased after overeating, other parameters did
not change significantly (Table 2). In the RSG group, plasma
insulin and TAG were increased and NEFA decreased after
overeating; plasma glucose, leptin and HDL-cholesterol did
not change significantly. RSG affected changes in plasma glu-
cose (P¼0·02) and TAG (P¼0·03), but not in plasma NEFA
(P¼0·94), insulin (P¼0·07), leptin (P¼0·15) and HDL-choles-
terol (P¼0·97). The difference in baseline insulin levels
between groups was not statistically significant (P¼0·11).
Rosiglitazone has no effect on PPARg transcriptional activity
in subcutaneous adipose tissue
The measured mRNA levels represent PPARg response genes
involved in adipogenesis, lipogenesis and lipolysis, i.e.
PPARg, aP2, adipsin, adiponectin and FIAF (Table 3). In
the RSG group, FIAF mRNA levels were significantly
decreased after overeating (median fold change 0·30,
P¼0·01), with a trend towards a decrease in the placebo
group. However, transcript levels were not statistically signifi-
cant affected by RSG treatment.
In both groups, there were strong correlations between
PPARg and aP2 mRNA at baseline, after overeating and
between changes in expression (rS 0·83–0·97, P,0·01), indi-
cating that PPARg mRNA levels are related to PPARg
activity. There were no significant correlations between
changes in PPARg or aP2 mRNA levels and fat storage.
Changes in adiponectin mRNA levels were positively corre-
lated with changes in PPARg or aP2 mRNA levels in both
groups (rS 0·64–0·93, P,0·05).
Rosiglitazone does not affect fat storage strategy
The median fat cell size decreased with 50 % in both the pla-
cebo and the RSG groups, but this change was not statistically
significant (P¼0·11 and 0·08 respectively; Table 4 and Fig. 1).
There was no statistically significant difference in changes in
fat cell size between treatments (P¼0·40); for the entire
group, fat cell size was decreased after overeating (P¼0·02).
These changes were accompanied by a, not statistically signifi-
cant, increase in DNA content (P¼0·77 placebo; P¼0·14
RSG). There were no differences in gene expression or
plasma parameters between subjects who showed fat cell
hypertrophy or hyperplasia after overeating for both groups.
Discussion
PPARg is the key regulator of adipose gene expression, whose
activity depends on transcriptional regulators and cofactors as
well as on ligand availability8. To study whether the avail-
ability of PPARg ligand is rate limiting in fat mass generation,
we studied the effects of RSG supplementation on several
PPARg-dependent processes. The results indicate that ligand
availability is of minor importance in subcutaneous fat mass
generation.
In both the placebo and RSG groups, PPARg and aP2
mRNA levels were correlated, which indicates activity of
PPARg as aP2 is primarily a PPARg response gene28,29. How-
ever, aP2 gene expression was not different between treat-
ments, suggesting that PPARg ligand availability is not rate
limiting for PPARg activity in subcutaneous adipose tissue
in healthy male subjects. Similar results were shown in type
II diabetic patients treated with pioglitazone for 24 weeks30.
Pioglitazone treatment did not change PPARg mRNA levels
and protein content, but baseline levels were strongly corre-
lated with the expression genes involved in fatty acid metab-
olism, synthesis and storage (acetyl-CoA synthetase,
lipoprotein lipase and fatty acid synthase)30. Unfortunately,
because of the small fat biopsies, we were not able to deter-
mine protein levels.
Adiponectin and adipsin are respectively early and late mar-
kers of adipocyte differentiation31,32. While plasma adipsin
concentrations are increased in obesity and correlate with
plasma insulin and TAG, adipsin mRNA in subcutaneous fat
tissue decreases with increasing BMI32. In contrast, plasma
adiponectin and mRNA expression are decreased in obesity
Table 2. Fasting plasma parameters at baseline and after self-induced overeating for the placebo and
rosiglitazone (RSG)-treated groups‡
(Mean values with their standard errors)
Placebo (n 10) RSG (n 10)
Baseline Overeating Baseline Overeating
Mean SE Mean SE Mean SE Mean SE
Glucose (mmol/l) 5·01 0·09 4·60** 0·06 4·84 0·10 4·93† 0·18
Insulin (mU/ml) 7·76 0·63 8·48 0·51 6·02 0·83 8·21†† 1·10
Leptin (ng/ml) 5·36 1·14 5·56 1·00 5·64 1·37 5·30 1·36
TAG (mmol/l) 0·59 0·04 1·20** 0·18 0·78 0·11 2·47**,† 0·70
NEFA (mmol/l) 0·21 0·03 0·11* 0·02 0·23 0·02 0·13* 0·03
HDL-cholesterol (mmol/l) 1·18 0·03 1·21 0·02 1·24 0·06 1·33 0·12
Overeating significantly different from baseline (within-group) using Wilcoxon’s paired signed rank test: *P,0·05, **P,0·01,
††P¼0·01.
Change in time significantly different between the placebo and RSG-treated groups using the Mann–Whitney U -test: †P,0·05.
‡ For details of subjects and procedures, see Subjects and methods.
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and in insulin-resistant patients, independent of obesity31 and
can be increased by thiazolidinedione treatment33. These
observations suggest an impaired fat cell function due to a dia-
betic state, which is typically associated with fat cell hypertro-
phy3. Indeed, fat cell size was shown to be negatively
correlated with adiponectin mRNA34. However, we found no
effect of RSG or overeating on adiponectin and adipsin
mRNA expression, suggesting that RSG has no short-term,
or at least an insignificant short-term, effect on adipose gene
expression in healthy, non-obese males.
Interestingly, RSG had a significant effect on TAG metab-
olism (i.e. tissue clearance and/or endogenous synthesis)
above the direct postprandial changes in substrate metabolism,
as the increase in fasting plasma TAG concentration after
overeating was significantly higher in the RSG group.
Although carbohydrate intake was higher in the RSG
group19, we believe this is not due to differences in nutrient-
related (i.e. fructose) TAG production as fruit intake was not
significantly different (data not shown). However, we
showed previously that whole-body fat oxidation was more
suppressed in the RSG group19 indicating that the increase
in TAG levels resulted from lowered NEFA oxidation in the
muscles while physical activity levels were not significantly
different between groups (data not shown). These results are
in strong contrast to the effects of RSG on the adipose
tissue of diabetic patients35. A factor directly related to
plasma TAG levels and positively regulated by PPARg is
FIAF, which is primarily produced by the adipose tissue and
owes its name to its strong up regulation in adipose tissue
and liver during fasting36. Prolonged high-fat feeding in
mice lowers plasma FIAF levels, but not adipose
tissue mRNA, and increases plasma TAG levels probably by
inhibiting lipoprotein lipase activity36,37. We did not find a
statistically significant difference in FIAF mRNA between
groups, but as adipose FIAF expression decreased during over-
eating in the RSG group, with a tendency towards a decrease
in the placebo group, FIAF may be involved in the observed
effects of RSG on TAG metabolism.
In addition to influencing TAG metabolism, RSG treatment
was accompanied by pronounced fluid retention. Recent
studies in mice show that PPARg has a direct role in renal
Na re-absorption, providing a mechanism for RSG-induced
fluid retention38,39. In addition, RSG increased weight and
vascular permeability selectively in adipose tissue, but not in
skeletal muscle, in lean, fatty and diabetic fatty Zucker rats,
indicating that insulin sensitivity is not essential for RSG to
induce fluid retention40.
In mice, high PPARg activity is associated with an increase
in fat cell size on a high-fat diet, while low PPARg activity is
associated with an increase in fat cell number41. In the present
study, fat cell size was decreased after overeating, suggesting
that fat was stored in newly recruited fat cells. RSG did not
influence this storage strategy.
We can speculate that the fat mass itself might be involved in
ligand availability, ligand binding and cofactor recruitment,
which might explain why RSG has different effects in non-
obese, healthy subjects compared with obese, diabetic patients.
Furthermore, despite the absence of increased transcriptional
activity of PPARg in the subcutaneous adipose tissue, the primary
target tissue of RSG, RSG induced pronounced changes in
Table 3. Median (inter-quartile range; IQR) fold changes in mRNA expression in subcutaneous
abdominal adipose tissue after self-induced overeating for the placebo and rosiglitazone (RSG)-
treated groups‡
Placebo (n 9) Fold change RSG (n 10) Fold change
Group effect
Median IQR P value* Median IQR P value* P value†
PPARg 1·46 1·34 0·31 1·09 1·86 0·96 1·00
aP2 1·35 1·63 0·52 1·21 1·79 0·72 0·88
Adiponectin 1·01 0·40 0·95 0·88 0·75 0·51 0·60
Adipsin 1·04 0·67 0·68 0·94 0·88 0·45 0·55
FIAF 0·63 0·65 0·14 0·30 0·34 0·01 0·13
* Using Wilcoxon’s paired signed rank test within groups.
† Using the Mann–Whitney U -test between groups.
‡ For details of subjects and procedures, see Subjects and methods.
aP2, adipocyte fatty acid-binding protein; FIAF, fasting-induced adipose factor.
Table 4. TAG and DNA contents of subcutaneous adipocytes at baseline and after self-induced overeating for the placebo
and rosiglitazone (RSG)-treated groups†
Placebo (n 9) RSG (n 9)
Baseline Overeating Baseline Overeating
Median IQR Median IQR Median IQR Median IQR
mg TAG/mg adipocytes 284·4 774·3 275·9 139·1 350·7 305·9 271·5 300·1
ng DNA/mg adipocytes 4·0 6·3 7·4 6·3 4·8 3·3 7·2 11
mg TAG/cell* 0·43 0·54 0·22 0·28 0·44 0·85 0·23 0·22
* Calculated from the mean DNA content per cell; 6 pg.
† For details of subjects and procedures, see Subjects and methods.
IQR, inter-quartile range.
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water balance and fat oxidation and tended to increase food
intake19. Although effects on transcriptional activity in other
organs cannot be ruled out, the adipose tissue is widely recognized
as the main site of action of PPARg agonists. In the absence of
differences in PPARg activity between treatments, alternative
pathways for RSG may have been involved. In rats, thiazo-
lidinediones acutely activate AMP-activated protein kinase in
adipose tissue, and also in skeletal muscle and liver. This effect
is most likely independent of PPARg-activated gene transcrip-
tion42. In turn, phosphorylation of PPARg by AMP-activated pro-
tein kinase inhibits its transcriptional activity43. However, we can
only speculate, as this experiment was not designed to study non-
transcriptional effects of RSG. The possibility of alternative path-
ways and, if any, their relative importance and changes in time
need to be investigated in further research.
In conclusion, the present results suggest that in healthy,
non-obese males the PPARg ligand RSG influences TAG
metabolism without increasing the transcriptional activity of
PPARg in the subcutaneous adipose tissue.
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